Who owns Avalyn Pharma Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AVLN from SEC Form 13F filings across 116 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 116 institutions disclosed 46.2M shares of Avalyn Pharma Inc. worth $1.32B — about 104.1% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
116
13F holders
$1.32B
value, 2026 filers
104.1%
of shares outstanding (46.2M sh)
37
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of AVLN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 6.2M | $176.2M | 0.0% | 13.9% | +6.0% |
| 2 | NOVO HOLDINGS A/S | 3.4M | $98.3M | 6.6% | 7.8% | -11.2% |
| 3 | SR ONE CAPITAL MANAGEMENT, LP | 3.3M | $94.3M | 8.2% | 7.5% | 0.0% |
| 4 | PERCEPTIVE ADVISORS LLC | 2.7M | $76.2M | 1.3% | 6% | 0.0% |
| 5 | MONTANOVA CAPITAL, LLC | 2.5M | $71.3M | 1.7% | 5.6% | 0.0% |
| 6 | NVP ASSOCIATES, LLC | 2.3M | $64.6M | 22.9% | 5.1% | 0.0% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 2.1M | $60.0M | 0.0% | 4.7% | -4.4% |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.8M | $51.7M | 0.0% | 4.1% | +4.6% |
| 9 | T. Rowe Price Investment Management, Inc. | 1.8M | $50.2M | 0.0% | 4% | +9.9% |
| 10 | Catalio Capital Management, LP | 1.7M | $48.4M | 9.0% | 3.8% | +1.4% |
| 11 | EVENTIDE ASSET MANAGEMENT, LLC | 1.4M | $39.2M | 0.5% | 3.1% | 0.0% |
| 12 | Bellevue Group AG | 1.4M | $38.5M | 0.8% | 3% | 0.0% |
| 13 | BlackRock, Inc. | 1.3M | $37.7M | 0.0% | 3% | +35.6% |
| 14 | Soleus Capital Management, L.P. | 1.0M | $29.0M | 1.0% | 2.3% | +143.2% |
| 15 | CITADEL ADVISORS LLC | 959,319 | $27.3M | 0.0% | 2.2% | 0.0% |
| 16 | ANDERA PARTNERS | 929,824 | $26.5M | 15.1% | 2.1% | 0.0% |
| 17 | Pivotal bioVenture Partners Investment Advisor LLC | 866,792 | $24.7M | 9.8% | 2% | -10.3% |
| 18 | JENNISON ASSOCIATES LLC | 866,491 | $24.7M | 0.0% | 2% | +6.6% |
| 19 | TPG GP A, LLC | 773,069 | $22.0M | 0.5% | 1.7% | 0.0% |
| 20 | VANGUARD CAPITAL MANAGEMENT LLC | 752,815 | $21.4M | 0.0% | 1.7% | +1.8% |
| 21 | BRAIDWELL LP | 744,460 | $21.2M | 0.9% | 1.7% | -7.1% |
| 22 | DEERFIELD MANAGEMENT COMPANY, L.P. | 731,000 | $20.8M | 0.3% | 1.6% | 0.0% |
| 23 | Rock Springs Capital Management LP | 662,918 | $18.9M | 1.0% | 1.5% | 0.0% |
| 24 | STATE STREET CORP | 554,004 | $15.8M | 0.0% | 1.2% | +73.7% |
| 25 | GEODE CAPITAL MANAGEMENT, LLC | 471,056 | $13.4M | 0.0% | 1.1% | +8.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.